Entrepreneur to Help Grow Bioprint Business

Bio-printing and microarray technology company Arrayjet has appointed Joe Keegan, a San Francisco-based biotechnology entrepreneur a respected leader in the life sciences industry, as non-executive director to help drive forward future opportunities and make a transformative impact for the business.

As Chief Executive Officer at ForteBio, Inc., Dr Keegan raised $25M, established product development and sales strategies that resulted in an annual revenue growth of 45%, and exited the company through its sale to Pall Corporation.

During his nine-year tenure at Molecular Devices Corporation, Dr. Keegan grew the company's revenues from $30M to $200M through internal growth and acquisitions.

With more than 30 years of experience in the life sciences industry Dr Keegan, currently serves on the boards of several companies in the sector, as well as the San Francisco Opera. He holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.

Dr Iain McWilliam, CEO of Arrayjet said: “For us to attract one of the most powerful names in the life sciences industry as a non-executive director speaks volumes for our international reach and development. Joe Keegan has demonstrated success after success in a long and remarkable career and will be an indispensable guide to the Arrayjet team as we move forward.”

Commenting on his appointment, Dr Keegan added: “I look forward to working with Iain McWilliam and the Arrayjet team on developing strategies that leverage their high throughput bio-printing technologies to accelerate growth. Moreover, contributing to make the best decisions regarding new product development and commercial execution will be top priorities.”

Arrayjet is supported by investment from the Archangels, the prominent Scottish-based business angel syndicate and the Scottish Investment Bank.